Skip to main content
Premium Trial:

Request an Annual Quote

Anne Bailey, Jeffrey White, Joseph Limber, John Lowe, Julie Glowacki, W. Stratford May, J. Donald Payne, Robert Butz, Ralph Brier


Anne Bailey has been appointed vice president of diagnostics and reagents at NaPro Biotherapeutics, and general manager of the company’s genomics division, the Boulder, Colo., company said Dec. 22. Bailey indirectly replaces Jeffrey White, who is stepping down Jan. 2 from his post as president of the company’s genomics division “to pursue other opportunities.” Bailey was most recently vice president of diagnostics at Variagenics, which merged with Hyseq in February to become Nuvelo. Bailey has also held management positions at Avitech Diagnostics, Photest Diagnostics, and Metpath. NaPro is seeking diagnostic and therapeutic applications for its gene editing technology in cancer and hereditary disease.

Joseph Limber joins Prometheus Laboratories of San Diego as president and chief executive officer and a member of the board. Previously, Limber served as interim CEO for Deltagen and was president and chief executive officer of Aclara BioSciences. Prior to that, he was president and COO of Praecis Pharmaceuticals. Limber holds a BA from Duquesne University.

John Lowe, Julie Glowacki, and W. Stratford May have joined the scientific advisory board of Velcura Therapeutics of Ann Arbor, Mich. Glowacki is a professor in the department of orthopedic surgery at the school of medicine as well as the department of oral/maxillofacial surgery at the school of dental medicine of Harvard University. Lowe is a professor in the department of pathology at the University of Michigan. He is also a research professor in the University of Michigan’s Life Sciences Institute and an investigator in the Howard Hughes Medical Institute. Additionally, he is an adjunct professor at the Burnham Institute in La Jolla, Calif. May is the director of the Shands Cancer Center, a professor in cancer research and on the faculty of the departments of medicine, biochemistry and molecular biology, as well as pharmacology and therapeutics.

J. Donald Payne joins the board of directors of Boston Biomedica, replacing William Wilson, who resigned on Oct. 3. Payne is president of Nanospectra Biosciences. Previously, he was senior vice president and CFO of Sensus Drug Development, which was sold to Pharmacia in 2001. He holds an undergraduate degree in business administration from Texas A&M University, and an MBA from Rice University.

Robert Butz will join MDS Pharma Services, as vice president, global regulatory affairs, and will be based at the company’s offices in King of Prussia, Pa.

Applied DNA Sciences has hired Ralph Brier as vice president of sales and marketing. Brier comes to Applied DNA Sciences from Sagem Morpho, where he was senior commercial, channel, and OEM business executive.

The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.